ABSTRACT
This article introduces papers based on presentations from a symposium entitled ‘Bone Morphogenic Protein Advisory Meeting in Orthopaedic Trauma’, where recent clinical findings with human bone morphogenetic protein‐2 (rhBMP‐2) were reviewed. It also presents two case studies which illustrate the clinical problems with the potential morbidity of tibial fractures and the potential benefits of the use of rhBMP‐2 at surgery. The article concludes with a summary of the symposium.
Tibial shaft fracture repair is associated with a significant financial burden on the patient, the health care providers and the medical insurance companies. It is anticipated that the clinical advantages of rhBMP-2 could lead to cost savings both inside and outside the hospital setting.